Insulin analogues and management of diabetes mellitus

Indian Journal of Pediatrics

Volumn 67, Issue 6, 2000, Pages 435-441

  Vaidyanathan, Balu ^a   Menon, P S N ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Insulin analogues; Insulin lispro; Management

Indexed keywords

INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN;

CARCINOGENICITY; CHILD; CONFERENCE PAPER; DIABETES MELLITUS; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HUMAN; RISK ASSESSMENT; SIDE EFFECT; TREATMENT INDICATION;

EID: 0033913588     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02859462     Document Type: Conference Paper

References (50)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med 1993; 329 : 977-86.
2. Holleman F, Hoekstra JBL. Insulin lispro. N Engl J Med 1997; 337 : 176-83.
3. Campbell RK, Campbell LK, White JR. Insulin lispro: Its role in the treatment of diabetes mellitus. Ann Pharmacol 1996; 30 : 1263-70.
4. Grossman LD. New insights into the clinical benefits of insulin lispro. Can J Diabetes Care 1998; 22 : 34-8.
5. Mudaliar SR, Linberg FA, Joyce M, et al. Insulin aspart (B28 asp-insulin): A fast acting analog of human insulin : Absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects. Diabetes Care 1999; 22 : 1501-6.
6. Bolli GB. Rationale for using combinations of short acting insulin analogue and NPH insulin at mealtime in the treatment of type 1 diabetes mellitus. J Pediatr Endocrinol Metab 1999; 12 : 737-44.
7. Sheker LJ, Sundell K. Modification in the 28-29 position of insulin B chain after binding to the IGF-1 receptor with minimal effect on insulin receptor binding. Diabetes 1991; 40 (suppl 1): 1684.
8. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. Lys (B28) Pro (B29)-human insulin. A rapidly absorbed analog of human insulin. Diabetes 1994; 43 : 396-402.
9. Holleman F, van den Brand JJG, Horen RARA et al. Comparison of Lys B28, Pro B29 human insulin analog and regular insulin in the correction of incidental hyperglycemia. Diabetes Care 1996; 19 : 1426-9.
10. Woodworth J, Howey D, Bowsher R, Lutz S, Santa P, Brady P. Lys B28 Pro B29 human insulin (k). Dose ranging versus Humulin R. Diabetes 1993; 42 (suppl. 1) : 54A (abstract).
11. Ling J, Hu M, Hagerup T, Campbell RK. Lispro insulin: Adsorption and stability in selected intravenous devices. Diabetes Edu 1999; 25 : 237-45.
12. Anderson JH, Brunelle RL, Kovinisto VA et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin analogue treatment. Diabetes 1997; 46 : 265-70.
13. Holleman F, Schmutt H, Rottiers R, Rees A, Symanowski S, Anderson JH. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. Diabetes Care 1998; 20 : 1827-32.
14. Wilde MI, McTavish D. Insulin lispro: A review of its pharmacological properties and therapeutic use in the management of diabetes mellitus. Drugs 1997; 54 : 597-614.
15. Davey P, Grainger D, Macmillan J, Rajan N, Aristides M, Gliksman M. Clinical outcomes with insulin lispro compared with human regular insulin: A metaanalysis. Clin Ther 1997; 19 : 656-74.
16. Puttagunta AL, Toth EL. Insulin lispro (Humalog), the first marketed insulin analogue: Indications, contraindications and need for further study. CMAJ 1998; 158 : 506-11.
17. Holcombe J, Zalani S, Arora V, Headlee S, Gill A. Insulin lispro results in less nocturnal hypoglycemia compared with regular insulin in adolescents with type 1 diabetes. Diabetes 1997; 46 (suppl 1) : 103A.
18. Heller SR, Amiel SA, Mansell P. Effect of fast acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group. Diabetes Care 1999; 22 : 1607-11.
19. Heller SR, Amiel SA, Janes J. Hypoglycemia during intensive insulin therapy: A comparison of lispro and regular insulin. Diabetes 1997; 46 (suppl 1) : 151A.
20. Ahmed AB, Home PD. The effect of the insulin analog lispro on night time blood glucose control in type 1 diabetic patients. Diabetes Care 1998; 21 : 32-7.
21. Brunelle BL, Llewelyn J, Anderson JH, Gale EA, Koivisto VA. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in parents with type 1 diabetes. Diabetes Care 1998; 21 : 1726-31.
22. Heinemann L. Hypoglycemia and insulin analogues: Is there a reduction in the incidence? J Diabetes Complications 1999; 13 : 105-14.
23. Berger M, Heinemann L. Are the presently available insulin analogues clinically beneficial? Diabetologia 1997; 40 : 1-96.
24. Lalli C, Ciofetta M, del Sindaco P et al. Long term intensive treatment of type 1 diabetes with short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999; 22 : 468-77.
25. Vignati L, Anderson JH, Iverson PW. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin dependent or noninsulin dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Clin Ther 1997; 19 : 1408-21.
26. Bolli GB, DiMarchi RD, Park G, Pramming S, Koivisto VA. Insulin analogs and their potential in management of diabetes mellitus. Diabetologia 1999; 42 : 1151-67.
27. Ronnemaa T, Vikari J. Reduction of snacks when switching from conventional soluble to lispro insulin. Effects on glycemic control and hypoglycemia. Diabetic Med 1998; 15 : 601-7.
28. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack TR. Insulin lispro in continuous subcutaneous insulin infusion. Results of a double blind crossover study. Diabetes 1997; 46 : 440-3.
29. Renner R, Pfutzner A, Trautmann M, Harzer O, Sauter K, Landgraf R. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. Diabetes Care 1999; 22 : 784-8.
30. Pein M, Hinselmann C, Pfutzner A, Dreyer M. Catheter disconnection in type 1 diabetic patients treated with CSII. Comparison of insulin lispro and human regular insulin. Diabetologia 1996; 36 (suppl 1) : A223 (abstract).
31. Attia N, Jones TW, Holcombe J, Tamborlane WV. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM. Diabetes Care 1998; 21 : 817-21.
32. B29 human insulin analog. Horm Metab Res 1994; 26 (suppl) : A34 (abstract).
33. Schernthaner G, Wein W, Sandholzer K, Equiluz-Bruck S, Bates PC, Birkett MA. Postprandial insulin lispro: A new therapeutic option for type 1 diabetic patients. Diabetes Care 1998; 21 : 570-3.
34. Kotsanos JG, Vignati L, Huster W. Health related quality of life results from multinational clinical trials of insulin lispro. Diabetes Care 1997; 20 : 948-58.
35. Tubiana-Rufi N, Munz-Licha G. Lispro analog and quality of life. Diabetes Metab 1997; 23 (suppl 3) : 58-62.
36. Lahtela JT, Knip M, Paul R, Antonen J, Salmi J. Severe insulin antibody mediated human insulin resistance: Successful treatment with insulin analog lispro. Diabetes Care 1997; 20 : 71-3.
37. Travaglini MT, Garg SK, Chase HP. Use of insulin lispro in the outpatient management of ketonuria. Arch Pediatr Adolesc Med 1998; 152 : 672-5.
38. Jovanovic L, Ilic S, Pettitt DJ et al. Metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care 1999; 22 : 1422-7.
39. Rutledge KS, Chase HP, Klingensmith GJ, Walravens PA, Slover RH, Garg SK. Effectiveness of postprandial Humalog in toddlers with diabetes. Pediatrics 1997; 100: 968-72.
40. Rami B, Schober E. Postprandial glycaemia after regular and lispro insulin in children and adolescents with diabetes. Eur J Pediatr 1997; 156 : 838-40.
41. Roper NA, Bilous RW. Resolution of lipohypertrophy following change of short acting insulin to insulin lispro (Humalog). Diabetes Med 1998; 15 : 1063-4.
42. Caixas A, Perez A, Payes A et al. Effects of a short acting insulin analog (Insulin lispro) versus regular insulin on lipid metabolism in insulin dependent diabetes mellitus. Metabolism 1998; 47 : 371-6.
43. Ish-Shalom D, Christofferson CT, Vorwerk P et al. Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia 1997; 40 : S25-S31.
44. Srachnan MW, Frier BM. Optimal time of administration of insulin lispro. Importance of meal composition. Diabetes Care 1998; 21 : 26-31.
45. Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: A multicenter randomized double blind crossover trial in type 1 diabetic patients. U.K. Insulin Aspart Study Group. Diabetes Care 1998; 21 : 1904-9.
46. Lindholm A, McEweri J, Riis AP. Improved postprandial glycemic control with insulin aspart. A randomised double blind crossover trial in type 1 diabetes. Diabetes Care 1999; 22 : 801-5.
47. Pieber T. Long acting insulin analogues: Can they provide a basal insulin level? J Pediatr Endocrinol Metab 1999; 12 : 745-50.
48. Pieber T, Eugene-Jolchine I, Derobet E. Efficacy and safety of HOE 901 in patients with type 1 diabetes: A four week randomised, NPH insulin controlled trial. Diabetes 1998; 47 : A63 (abstract).
49. Markussen J, Havelund S, Kurtzhals P et al. Soluble fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 1996; 39 : 281-8.
50. Roach P, Yue L, Arora V. Improved postprandial glycemic control during treatment with Humalog Mix 25, a novel protamine based insulin lispro formulation. Humalog Mix 25 Study Group. Diabetes Care 1999; 22 : 1258-61.58-61.